Brokerages Set VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Price Target at $0.95

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have earned a consensus rating of “Reduce” from the five brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $0.95.

A number of research analysts have recently weighed in on VTGN shares. Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Wall Street Zen upgraded VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Stifel Nicolaus lowered shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 target price for the company. in a report on Wednesday, December 17th.

More VistaGen Therapeutics News

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Vistagen will meet with investors at March conferences (Leerink one‑on‑ones in Miami and Stifel virtual CNS forum), giving management an opportunity to present clinical progress and address questions — a potential stabilizing/clarifying event for investors. Read More.
• Neutral Sentiment: There is a firm deadline (March 16, 2026) for investors to seek lead‑plaintiff status in the filed federal securities suit; the class period is reported as April 1, 2024–December 16, 2025. This is procedural but concentrates filings and media attention near the deadline, which can increase short‑term volatility. Read More.
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Rosen, Pomerantz, Bragar Eagel & Squire, Faruqi & Faruqi, Gross Law Firm, etc.) have publicly notified shareholders of a securities‑fraud lawsuit and are soliciting clients — signaling elevated litigation risk, potential future settlement costs, and reputational damage that typically weigh on biotech microcaps like VTGN. Repeated alerts amplify media coverage and likely contributed to selling pressure today. Read More.

VistaGen Therapeutics Stock Down 0.8%

Shares of VistaGen Therapeutics stock opened at $0.61 on Monday. The stock’s 50-day simple moving average is $0.62 and its 200-day simple moving average is $2.59. VistaGen Therapeutics has a 52 week low of $0.43 and a 52 week high of $5.14. The company has a market capitalization of $23.97 million, a price-to-earnings ratio of -0.32 and a beta of 0.29.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.06. The business had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.14 million. On average, equities analysts expect that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Institutional Trading of VistaGen Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Luminus Management LLC purchased a new stake in VistaGen Therapeutics in the fourth quarter worth about $232,000. Two Sigma Investments LP raised its holdings in shares of VistaGen Therapeutics by 223.5% in the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after purchasing an additional 199,958 shares in the last quarter. Millennium Management LLC lifted its position in shares of VistaGen Therapeutics by 853.0% in the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after purchasing an additional 176,369 shares during the period. OMERS ADMINISTRATION Corp bought a new position in shares of VistaGen Therapeutics during the fourth quarter valued at approximately $68,000. Finally, Jane Street Group LLC bought a new position in shares of VistaGen Therapeutics during the second quarter valued at approximately $190,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.